Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-09-27 23:33:45 - browse：1

Earlier this month, Intellia Therapeutics announced it was scrapping plans to include U.S.-based sites in one of its mid-stage CRISPR trials after the Food and Drug Administration requested additional data to support including female patients of childbearing potential. The move left many researchers wondering whether the specter of accidental germline transmission — which haunted early gene therapy trials — had now risen over the field of gene editing.

Over the weekend, Intellia sought to assure the gene editing community that no such thing is happening. At a meeting at Cold Spring Harbor Laboratory that drew more than 400 of the field’s top scientists, the company shared more detailed information about studies it has conducted to assess the risks that renegade CRISPR components could be getting into an egg or sperm. These studies demonstrate “that there’s no evidence of vertical germline transmission of those edits,” Jonathan Phillips, head of pharmacology and toxicology at Intellia, said during a presentation Saturday.

Intellia is one of the leading companies working to advance in vivo gene editing therapies. In a landmark study published in the New England Journal of Medicine in 2021, Intellia revealed data from six patients in its trial for a transthyretin amyloidosis therapy — showing for the first time that it was possible to precisely alter the DNA of particular cells within the human body to treat disease with a one-time infusion of CRISPR. Included in the supplementary material was a redacted version of the company’s package requesting authorization to start its clinical trial. It noted that during toxicology studies in non-human primates, Intellia scientists discovered that editing had taken place at low levels in organs other than the liver, including the spleen and adrenal glands. In three out of 12 female monkeys, they also found editing in the animals’ ovaries.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Dementia risk linked to living in disadvantaged areas: Study

hotspot

WSS

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

There’s a way to spot data fakery. All journals should be using it

Walmart eyes Medicare Advantage provider ChenMed

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Food makers to regulators: Ultra

Food makers to regulators: Ultra

Wikipedia

Wikipedia

focus

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Generate Biomedicines machine learning biotech raises $273M

Virginia high school admissions case could be legal follow

IRA could hurt research into orphan drugs for rare diseases

Heart attack and stroke risk calculators need revising

New weight loss drugs vying to be the next Wegovy or Mounjaro

Apple is now the first public company to be valued at $3 trillion

The stock market has soared this year, but will it last? Experts weigh in

hotspot

Generate Biomedicines machine learning biotech raises $273M

There’s a way to spot data fakery. All journals should be using it

Dementia risk linked to living in disadvantaged areas: Study

'CMA Fest' 2023: How to watch, who is performing and more

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

Telehealth startups are trying to fill the menopause care vacuum

hotspot

hotspot

hotspot

focus